Investing
The company's complete blood count analyzer uses artificial intelligence to quickly measure biomarkers from a fingerstick or venous sample.
The listing could happen either later this year or in early 2021, Reuters reports.
The fund aims to bring UCL’s academic research in life, computer and physical sciences to commercial reality.
The new service will let patients communicate with general practitioners, mental health clinicians and specialists.
The startup's approach combines a low-cost digital-imaging device for hospitals with a comprehensive medical-imaging software platform.
Also: DarioHealth announced $28.6 million private placement transaction; StuffThatWorks launches with $9 million seed funding.
As part of the deal, Northwest Capital's Edward Yip and General Catalyst's Holly Maloney are joining Tempo's board.
Users can adjust settings for the devices through a corresponding app.
Funds will be used to expand across the UK, Ireland, DACH and BENELUX.
The roughly three-year-old company says it now has a post-money valuation over $1 billion.